Avacta announces AVA6000 dose escalation results
Candidate is a cancer therapy that has been chemically modified with Avacta’s pre|CISION platform
Read More
Tag: Avacta
Avacta doses first patient in pivotal phase 1a trial
Individual receives AVA6000 treatment as part of additional dose escalating study
Read More
Avacta announces clinical study of AVA6000
Pro-doxorubicin will advance to the fourth dose following a positive review of safety and tolerability
Read More
Avacta announces escalation in clinical study of AVA6000
AVA6000 is a novel form of doxorubicin that has been modified using Avacta’s delivery platform to improve safety
Read More
Avacta gets MHRA green-light to start phase I trial for ‘pro-drug’ chemotherapy
AVA6000 is pro-drug form of the chemotherapy doxorubicin, modified using Avacta’s pre|CISION chemistry
Read More
Avacta and Cytiva team up for COVID-19
The firms will develop and manufacture an Affimer-based point-of-care rapid test for screening large populations for COVID-19 infection
Read More
Avacta, ADC Theraputics sign collaboration and option agreement
The partnership will focus on developing potent Affimer-drug conjugates.
Read More
Avacta, Glythera link to develop drug conjugates
UK companies Avacta and Glythera have sealed a licensing deal to develop drug conjugates using their combined technologies.
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
